Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.

ABSTRACT:

Background

Most patients with major depressive disorder (MDD) report clinically significant sleep problems. Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup. This study investigated this question using data from the CO-MED trial.

Methods

Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram+placebo, (2) bupropion-sustained-release+escitalopram, or (3) venlafaxine-extended-release+mirtazapine. We compared baseline characteristics, tolerability, and treatment outcomes at 12 and 28 weeks for patients

SUBMITTER: Sung SC 

PROVIDER: S-EPMC4340746 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature